Trial Profile
Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 25 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2013 Planned end date changed from 1 May 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 05 Mar 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.